ExpertAsia-improving patient outcomes - Introducing PCDx - targeted diagnostics for oncology patients
WHAT IS PARADIGM’S PCDx TEST?
The PCDx test is a Next-Generation Sequencing based
diagnostic genomic test that offers a more targeted,
personalized approach to cancer treatment by
interrogating and identifying the underlying genomic
alterations of your tumor’s DNA & RNA. The information
provided by this test assists your treating physician in
developing a more informed and individually tailored
treatment strategy for your cancer.

WHAT IS NEXT-GENERATION SEQUENCING (NGS)?
NGS is a revolutionary laboratory technology that is
utilized by Paradigm’s PCDx test to rapidly, accurately
and confidently assess genes of a specific tumor sample
and identify potentially treatable genomic alterations in
your cancer’s DNA & RNA.

WHY ARE GENOMIC ALTERATIONS IMPORTANT FOR
GUIDING CANCER THERAPY?
Genomic alterations are changes in the tumor’s DNA
that can impact the way that specific cells and cancers
behave. While most genomic changes are part of our
normal biology and do not have a negative impact,
some can lead to cancer. While cancers are typically
caused by alterations within a few hundred very specific
genes, only a sub-set of those genes are classified
as “actionable” or associated with a drug therapy.
Research has shown that using therapies that “target”
these actionable gene alterations can lead to better
patient outcomes with fewer side effects.

HOW WILL THIS GENOMIC INFORMATION HELP
GUIDE MY TREATMENT?
The results of your testing will be sent to your treating
physician in a clinical report, which will outline:
• The testing performed
• The genomic alterations that were identified
• Information on any potential treatment strategies,
including clinical trials that could be of benefit
based on your tumor’s analysis. Your physician may
incorporate this data as they develop your
individualized treatment strategy.



Website Builder provided by  Vistaprint